Core Insights - Alkermes plc presented clinical data on LYBALVI® at the 2024 Congress of the Schizophrenia International Research Society, highlighting its long-term safety, tolerability, and treatment durability in patients with schizophrenia and bipolar I disorder [1][2][3] Patient Disposition - A total of 523 participants received at least one dose of LYBALVI in the study, with 188 (35.9%) completing the study after two to four years of treatment [2] - Of the 451 patients eligible for at least two years of treatment, 242 (53.7%) participated, while 335 patients had the opportunity for four years of treatment, with 109 (32.5%) completing it [2] Weight and Metabolic Changes - For the two-year assessment, the mean change in body weight was an increase of 0.84 kg, while waist circumference decreased by 0.56 cm [2] - In the four-year assessment, the mean change in body weight was an increase of 2.65 kg, and waist circumference increased by 1.37 cm, with minimal changes in lipid and glycemic parameters [2] Adverse Events - The adverse event profile was consistent with previous studies, with 60% of participants reporting at least one adverse event [2] - Common adverse events included weight increase, headache, anxiety, insomnia, somnolence, nausea, and weight decrease, most of which were mild to moderate in severity [2] Symptom Control - Patients' symptoms of schizophrenia or bipolar I disorder remained stable, as measured by the Clinical Global Impression of Severity (CGI-S) scale, with mean changes from baseline of -0.18 for two years and -0.24 for four years [2][3] Study Design - The study was an international, multicenter, phase 3, open-label extension assessing LYBALVI's long-term safety and efficacy for up to four years [4] - Patients were enrolled within seven days of completing prior phase 3 clinical trials, with a daily dose of LYBALVI ranging from 5-20 mg of olanzapine and 10 mg of samidorphan [4][5] Company Overview - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines for neurological disorders, with a portfolio that includes treatments for schizophrenia and bipolar I disorder [22]

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Alkermes (ALKS) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 24.90%.For the ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Sc ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

The most recent trading session ended with Alkermes (ALKS) standing at $29.45, reflecting a +1.76% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 1.03%. Meanwhile, the Dow gained 0.34%, and the Nasdaq, a tech-heavy index, added 1.51%.The drugmaker's shares have seen an increase of 8.39% over the last month, surpassing the Medical sector's gain of 2.1% and the S&P 500's gain of 3.21%.Market participants will be closely following the financial results of Alkerme ...

DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. Alkermes Announces Appointment o ...

In the latest trading session, Alkermes (ALKS) closed at $29.69, marking a -0.37% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.52%. On the other hand, the Dow registered a gain of 0.12%, and the technology-centric Nasdaq increased by 0.9%.The drugmaker's stock has climbed by 10.17% in the past month, exceeding the Medical sector's gain of 5.15% and the S&P 500's gain of 3.85%.Analysts and investors alike will be keeping a close eye on the performance of Alkermes ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare. Essentially, they are responsible for improving current treatments by placing a large portion of their earnings back into research. Many people imagine these companies as quite risky, as a result, since many don’t have proven earnings. However, because of the large amount of spending back into the business, they offer explosive growth. With AI being all we practically ...